<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923386</url>
  </required_header>
  <id_info>
    <org_study_id>Macknofsky 1</org_study_id>
    <nct_id>NCT04923386</nct_id>
  </id_info>
  <brief_title>mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels</brief_title>
  <official_title>Effect of mRNA Based-Covid-19 Vaccine on Blood Glucose Levels Recorded by Continuous Glucose Monitoring in Patients With a History of Diabetes Mellitus Type I and Type II.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Levenson, David I., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Levenson, David I., M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if patients with a history of Diabetes Mellitus Type I or II developed a change&#xD;
      in blood glucose levels as reported on Continuous glucose monitoring devices (CGMS) within&#xD;
      the first week following administration of each dose of the COVID-19 vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective review of all patient data from the Dexcom and Libre CGMS devices available&#xD;
      at a single site, solo endocrinology practice will be obtained. This data will include&#xD;
      fasting morning glucose, postprandial glucose, and daily glucose area under the curve for&#xD;
      seven days following vaccination administration, as well as daily glucose area under the&#xD;
      curve seven days prior to vaccine administration that will be used as a control. Patients&#xD;
      &gt;=18 y/o with a history of Diabetes Mellitus Type I or Type II will be selected. Brand of&#xD;
      vaccine administered (Moderna or Pfizer-BioNTech) and the change in average blood glucose,&#xD;
      peak blood glucose, and percentage of time spent in normal range as well as above average&#xD;
      range of blood glucose level following vaccine administration will be assessed. Patients will&#xD;
      fill out a visual analog symptom scale based on how symptomatic and uncomfortable they were&#xD;
      following each dose of the COVID-19 vaccine. Patients will describe side effects that they&#xD;
      experienced following each dose of the COVID-19 vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AUC glucose level above expected baseline</measure>
    <time_frame>7 days</time_frame>
    <description>Change in area under the curve glucose level above expected baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in peak glucose level above expected baseline</measure>
    <time_frame>7 days</time_frame>
    <description>Change in peak glucose level above expected baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood glucose levels above expected baseline</measure>
    <time_frame>7 days</time_frame>
    <description>Change in fasting blood glucose levels above expected baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Hyperglycemia</condition>
  <condition>Vaccine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Diabetics who receive mRNA COVID-19 vaccine</arm_group_label>
    <description>Patients that have a history of Diabetes Mellitus Type I or Type II who received Pfizer-N-Biotech or Moderna mRNA COVID-19 vaccines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None (not interventional)</intervention_name>
    <description>This is not an intervention</description>
    <arm_group_label>Diabetics who receive mRNA COVID-19 vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible patients in the PI's database.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Diabetes Mellitus Type I or Type II&#xD;
&#xD;
          -  Received the Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt;18y/o.&#xD;
&#xD;
          -  Patients that did not receive a COVID-19 vaccine.&#xD;
&#xD;
          -  Patients who did not have a CGMS downloaded for a week prior and a week after&#xD;
             vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David I Levenson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>East Coast Medical Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David I Levenson, M.D.</last_name>
    <phone>561-391-4441</phone>
    <email>levensonx6@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brandon S Macknofsky, B.S.</last_name>
    <phone>954-654-5708</phone>
    <email>bmacknof@health.fau.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>East Coast Medical Associates</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Levenson, MD</last_name>
      <phone>561-702-6089</phone>
      <email>levensonx6@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Brandon Macknofsky, BS</last_name>
      <phone>954-654-5708</phone>
      <email>bmacknof@health.fau.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Levenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Levenson, David I., M.D.</investigator_affiliation>
    <investigator_full_name>David I. Levenson, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mRNA Vaccine</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>COVID-19 Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

